Quick answer: Both were recommended by the FDA’s advisory committee in July 2026, and both received a fraction of the coverage that BPC-157 and TB-500 did. They also share something more interesting than a vote: nearly their entire published record comes from a single national research tradition, which is exactly the criticism FDA staff raised […]
Quick answer: An FDA import alert lets the agency detain shipments from a named foreign facility automatically, without opening a single box. It is called Detention Without Physical Examination, and once a facility is on the list, every subsequent shipment is flagged by default. Three of these alerts sit directly over the peptide supply chain […]
Quick answer: “Research use only” is a statement of intended use, not a disclaimer that protects a seller. Under federal law, what a product legally is depends on what the people selling it intend it for - and intent is judged by everything they say and do, not by the sentence at the bottom of […]
Quick answer: In July 2026, an FDA advisory committee recommended six peptides - BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon - for the 503A Bulks List. Those votes were advisory, not binding, and nothing is authorized today. The more consequential news is what comes next: FDA has signaled it will review a second group, including […]
Account access required
Sign in with an existing account or register as a qualified research customer.
Welcome back. Enter your account details to continue.
Register for research-customer access.
BioPure products are intended only for lawful research, laboratory, and analytical use. They are not for human or animal consumption and are not intended for medical, diagnostic, or therapeutic use. Review our Terms of Use.